TY - JOUR
T1 - Intranasal application of stem cells and their derivatives as a new hope in the treatment of cerebral hypoxia/ischemia
T2 - a review
AU - Salehi, Mohammad Saied
AU - Jurek, Benjamin
AU - Karimi-Haghighi, Saeideh
AU - Nezhad, Nahid Jashire
AU - Mousavi, Seyedeh Maryam
AU - Hooshmandi, Etrat
AU - Safari, Anahid
AU - Dianatpour, Mehdi
AU - Haerteis, Silke
AU - Miyan, Jaleel A
AU - Pandamooz, Sareh
AU - Borhani-Haghighi, Afshin
N1 - Funding Information:
Research funding: This study was financially supported by Shiraz University of Medical Sciences (Grant number: 23290).
Publisher Copyright:
© 2022 Walter de Gruyter GmbH, Berlin/Boston 2022.
PY - 2022/8/26
Y1 - 2022/8/26
N2 - Intranasal delivery of stem cells and conditioned medium to target the brain has attracted major interest in the field of regenerative medicine. In pre-clinical investigations during the last ten years, several research groups focused on this strategy to treat cerebral hypoxia/ischemia in neonates as well as adults. In this review, we discuss the curative potential of stem cells, stem cell derivatives, and their delivery route via intranasal application to the hypoxic/ischemic brain. After intranasal application, stem cells migrate from the nasal cavity to the injured area and exert therapeutic effects by reducing brain tissue loss, enhancing endogenous neurogenesis, and modulating cerebral inflammation that leads to functional improvements. However, application of this administration route for delivering stem cells and/or therapeutic substances to the damaged sites requires further optimization to translate the findings of animal experiments to clinical trials.
AB - Intranasal delivery of stem cells and conditioned medium to target the brain has attracted major interest in the field of regenerative medicine. In pre-clinical investigations during the last ten years, several research groups focused on this strategy to treat cerebral hypoxia/ischemia in neonates as well as adults. In this review, we discuss the curative potential of stem cells, stem cell derivatives, and their delivery route via intranasal application to the hypoxic/ischemic brain. After intranasal application, stem cells migrate from the nasal cavity to the injured area and exert therapeutic effects by reducing brain tissue loss, enhancing endogenous neurogenesis, and modulating cerebral inflammation that leads to functional improvements. However, application of this administration route for delivering stem cells and/or therapeutic substances to the damaged sites requires further optimization to translate the findings of animal experiments to clinical trials.
KW - conditioned medium
KW - hypoxic brain
KW - ischemic brain
KW - nasal delivery
KW - secretome
KW - stem cell
U2 - 10.1515/revneuro-2021-0163
DO - 10.1515/revneuro-2021-0163
M3 - Review article
C2 - 35130375
SN - 0334-1763
VL - 33
SP - 583
EP - 606
JO - Reviews in the Neurosciences
JF - Reviews in the Neurosciences
IS - 6
ER -